Friday, December 19, 2014 2:45:34 PM
It was Dr. Seymour who originally said the new facility was not necessary for material production to complete Tox. This was well after they had determined they would need 2.5Kg.
Are you saying he is not familiar with bio science?
-------------------------------
How come, if these details were true, we only get them after the fact?
We were told for a long time Tox would only take 6-9 months and would be completed by "worst" case scenario Q1 2015.
Do you see how it looks like the goal posts have been moved and now it's "of course it will take longer this is how these things work" but the CEO gave us an entirely different map and set of expectations stating that is NOT how they work.
He even bragged in email about having his lawyers sic on people with implied threats to their bosses at work for daring to question Seymour's timeframes. I would say that is quite a note of confidence he had.
Now it's "Anyone who is familiar with bio science knows...." WTF?
The shareholders who plopped down their life savings at $5.70 based on Seymour promising a great 2014 and Tox completed or almost completed by now aren't familar with bio science. That's why we turned to our CEO for guidance. And that guidance turned to either be total bullshit from the beginning or the result of severe incompetence.
The SwingTrade Portfolio is up 42.1% YTD through 8/8/2014, 83.5% in 2013, and 537.4% since inception.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=105141243
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM